Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Shares Outstanding (Weighted Average) (2018 - 2026)

Immunovant filings provide 8 years of Shares Outstanding (Weighted Average) readings, the most recent being $175.4 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 19.69% to $175.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $175.4 million through Dec 2025, up 19.69% year-over-year, with the annual reading at $151.6 million for FY2025, 9.76% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $175.4 million in Q4 2025 for Immunovant, up from $173.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $175.4 million in Q4 2025 and bottomed at $87.8 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $131.5 million, with a median of $130.8 million recorded in 2023.
  • The largest annual shift saw Shares Outstanding (Weighted Average) skyrocketed 103.14% in 2021 before it grew 8.1% in 2024.
  • Immunovant's Shares Outstanding (Weighted Average) stood at $107.4 million in 2021, then grew by 12.3% to $120.7 million in 2022, then rose by 12.36% to $135.6 million in 2023, then increased by 8.1% to $146.6 million in 2024, then increased by 19.69% to $175.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Shares Outstanding (Weighted Average) are $175.4 million (Q4 2025), $173.6 million (Q3 2025), and $170.9 million (Q2 2025).